We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

105 hedge funds and large institutions have $280M invested in Lexicon Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

329% more call options, than puts

Call options by funds: $296K | Put options by funds: $69K

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

19% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 32

7% more funds holding

Funds holding: 98 → 105 (+7)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.25% less ownership

Funds ownership: 81.08% → 77.83% (-3.3%)

22% less capital invested

Capital invested by funds: $357M → $280M (-$77.6M)

Holders
105
Holders Change
+7
Holders Change %
+7.14%
% of All Funds
1.69%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
38
Reduced
32
Closed
7
Calls
$296K
Puts
$69K
Net Calls
+$227K
Net Calls Change
+$27K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$576K
2
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$286K
3
PHP
Parkman Healthcare Partners
Connecticut
+$250K
4
SSA
Schonfeld Strategic Advisors
New York
+$249K
5
Fisher Asset Management
Fisher Asset Management
Washington
+$244K

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.83M
2
AQR Capital Management
AQR Capital Management
Connecticut
-$539K
3
Group One Trading
Group One Trading
Illinois
-$224K
4
Natixis Advisors
Natixis Advisors
Massachusetts
-$212K
5
PA
Pinnacle Associates
New York
-$209K
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
1
Artal Group
Luxembourg
$171M – – –
BI
2
BVF Inc
California
$30.8M – – –
BlackRock
3
BlackRock
New York
$11.2M +$197K +92,485 +2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$10M +$128 +60 +0%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$10M -$66.6K -31,314 -0.6%
JP Morgan Chase
6
JP Morgan Chase
New York
$6.26M +$107K +50,365 +2%
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$5.88M +$72.3K +33,996 +1%
NMC
8
NEA Management Company
Maryland
$4.55M – – –
PA
9
Pinnacle Associates
New York
$3.69M -$209K -98,430 -5%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$3.07M +$82.8K +38,919 +2%
State Street
11
State Street
Massachusetts
$2.9M +$113K +52,906 +4%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$2.57M -$4.83M -2,269,369 -63%
Millennium Management
13
Millennium Management
New York
$2.25M +$576K +270,656 +30%
Northern Trust
14
Northern Trust
Illinois
$1.5M +$110K +51,461 +7%
Fisher Asset Management
15
Fisher Asset Management
Washington
$1.38M +$244K +114,715 +19%
Charles Schwab
16
Charles Schwab
California
$1.33M +$71.2K +33,462 +5%
PHP
17
Parkman Healthcare Partners
Connecticut
$804K +$250K +117,588 +39%
Renaissance Technologies
18
Renaissance Technologies
New York
$751K -$187K -88,090 -18%
CAM
19
ClariVest Asset Management
California
$744K -$6.45K -3,031 -0.8%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$623K +$73.1K +34,358 +12%
Goldman Sachs
21
Goldman Sachs
New York
$509K +$54.1K +25,436 +11%
Russell Investments Group
22
Russell Investments Group
United Kingdom
$474K – – –
N
23
Nuveen
North Carolina
$467K -$132K -61,866 -20%
T. Rowe Price Associates
24
T. Rowe Price Associates
Maryland
$371K +$1.78K +838 +0.4%
Swiss National Bank
25
Swiss National Bank
Switzerland
$348K +$20.2K +9,500 +5%
1
2 3 4 5

LXRX Hedge Fund Activity: Q4 2022 in Review

105 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2022, worth a combined $280M — down 22% from $357M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new LXRX positions and 7 closed out — a net gain of 7 holders — while 38 added to existing stakes and 32 trimmed.

The largest buyer was Millennium Management, adding an estimated $576K. The largest seller was Point72 Asset Management, cutting an estimated $4.83M.

  • 105 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2022, up from 98 in Q3 2022.
  • Funds reported $280M of Lexicon Pharmaceuticals stock for Q4 2022, down 22% quarter-over-quarter.
  • 14 funds opened new Lexicon Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of +7 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $576K added.
  • The largest Lexicon Pharmaceuticals seller in Q4 2022 was Point72 Asset Management, an estimated $4.83M sold.

Based on aggregated 13F filings for Q4 2022.